Cargando…

Characterization of human follicular thyroid cancer cell lines in preclinical mouse models

Follicular thyroid cancer (FTC) is the second most common type of thyroid cancers. In order to develop more effective personalized therapies, it is necessary to thoroughly evaluate patient-derived cell lines in in vivo preclinical models before using them to test new, targeted therapies. This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Reeb, Ashley N, Ziegler, Andrea, Lin, Reigh-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002955/
https://www.ncbi.nlm.nih.gov/pubmed/26830329
http://dx.doi.org/10.1530/EC-15-0114
_version_ 1782450594230829056
author Reeb, Ashley N
Ziegler, Andrea
Lin, Reigh-Yi
author_facet Reeb, Ashley N
Ziegler, Andrea
Lin, Reigh-Yi
author_sort Reeb, Ashley N
collection PubMed
description Follicular thyroid cancer (FTC) is the second most common type of thyroid cancers. In order to develop more effective personalized therapies, it is necessary to thoroughly evaluate patient-derived cell lines in in vivo preclinical models before using them to test new, targeted therapies. This study evaluates the tumorigenic and metastatic potential of a panel of three human FTC cell lines (WRO, FTC-238, and TT1609-CO2) with defined genetic mutations in two in vivo murine models: an orthotopic thyroid cancer model to study tumor progression and a tail vein injection model to study metastasis. All cell lines developed tumors in the orthotopic model, with take rates of 100%. Notably, WRO-derived tumors grew two to four times faster than tumors arising from the FTC-238 and TT2609-CO2 cell lines. These results mirrored those of a tail vein injection model for lung metastasis: one hundred percent of mice injected with WRO cells in the tail vein exhibited aggressive growth of bilateral lung metastases within 35 days. In contrast, tail vein injection of FTC-238 or TT2609-CO2 cells did not result in lung metastasis. Together, our work demonstrates that these human FTC cell lines display highly varied tumorigenic and metastatic potential in vivo with WRO being the most aggressive cell line in both orthotopic and lung metastasis models. This information will be valuable when selecting cell lines for preclinical drug testing.
format Online
Article
Text
id pubmed-5002955
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-50029552016-08-30 Characterization of human follicular thyroid cancer cell lines in preclinical mouse models Reeb, Ashley N Ziegler, Andrea Lin, Reigh-Yi Endocr Connect Research Follicular thyroid cancer (FTC) is the second most common type of thyroid cancers. In order to develop more effective personalized therapies, it is necessary to thoroughly evaluate patient-derived cell lines in in vivo preclinical models before using them to test new, targeted therapies. This study evaluates the tumorigenic and metastatic potential of a panel of three human FTC cell lines (WRO, FTC-238, and TT1609-CO2) with defined genetic mutations in two in vivo murine models: an orthotopic thyroid cancer model to study tumor progression and a tail vein injection model to study metastasis. All cell lines developed tumors in the orthotopic model, with take rates of 100%. Notably, WRO-derived tumors grew two to four times faster than tumors arising from the FTC-238 and TT2609-CO2 cell lines. These results mirrored those of a tail vein injection model for lung metastasis: one hundred percent of mice injected with WRO cells in the tail vein exhibited aggressive growth of bilateral lung metastases within 35 days. In contrast, tail vein injection of FTC-238 or TT2609-CO2 cells did not result in lung metastasis. Together, our work demonstrates that these human FTC cell lines display highly varied tumorigenic and metastatic potential in vivo with WRO being the most aggressive cell line in both orthotopic and lung metastasis models. This information will be valuable when selecting cell lines for preclinical drug testing. Bioscientifica Ltd 2016-03-01 /pmc/articles/PMC5002955/ /pubmed/26830329 http://dx.doi.org/10.1530/EC-15-0114 Text en © 2016 The authors http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Reeb, Ashley N
Ziegler, Andrea
Lin, Reigh-Yi
Characterization of human follicular thyroid cancer cell lines in preclinical mouse models
title Characterization of human follicular thyroid cancer cell lines in preclinical mouse models
title_full Characterization of human follicular thyroid cancer cell lines in preclinical mouse models
title_fullStr Characterization of human follicular thyroid cancer cell lines in preclinical mouse models
title_full_unstemmed Characterization of human follicular thyroid cancer cell lines in preclinical mouse models
title_short Characterization of human follicular thyroid cancer cell lines in preclinical mouse models
title_sort characterization of human follicular thyroid cancer cell lines in preclinical mouse models
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002955/
https://www.ncbi.nlm.nih.gov/pubmed/26830329
http://dx.doi.org/10.1530/EC-15-0114
work_keys_str_mv AT reebashleyn characterizationofhumanfollicularthyroidcancercelllinesinpreclinicalmousemodels
AT zieglerandrea characterizationofhumanfollicularthyroidcancercelllinesinpreclinicalmousemodels
AT linreighyi characterizationofhumanfollicularthyroidcancercelllinesinpreclinicalmousemodels